Howe & Rusling’s Clovis Oncology, Inc. CLVS Stock Holding History

Howe & Rusling’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-250	Closed	-$3K	–	911
2019 Q4	$3K	Buy	+250	New	+$1.82K	﹤0.01%	644

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Howe & Rusling's CLVS Position: Q1 2020 in Review

Howe & Rusling sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 250 shares — an estimated $3K sold.

Howe & Rusling first reported a position in CLVS in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

Howe & Rusling reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
Howe & Rusling sold 250 Clovis Oncology, Inc. shares in Q1 2020, an estimated $3K.
Howe & Rusling first reported a position in Clovis Oncology, Inc. in Q4 2019 and held it in 1 quarter.
Howe & Rusling's Clovis Oncology, Inc. position peaked at $3K in Q4 2019.
154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.